Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 109 companies set new 52-week lows.
NexImmune Announces Research Collaboration With Rutgers, The State University of New Jersey, Related To Neuroendocrine Tumor Targets
NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T
NexImmune Reports Formation Of Autoimmune, Infectious Diseases Scientific Advisory Board
NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T
NexImmune Announced Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma at ASH 2021
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-a
Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $21
Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $30 to $21.
NexImmune Q3 EPS $(0.65) Misses $(0.64) Estimate
NexImmune (NASDAQ:NEXI) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.64) by 1.56 percent.
Earnings Scheduled For November 12, 2021
Companies Reporting Before The Bell
• Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million.